
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1105635/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multiâ€biomarker panel prediction model for diagnosis ofÂpancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 122-132.	2.6	9
2	Influence of Hypofractionated Versus Conventional Fractionated Postmastectomy Radiation Therapy in Breast Cancer Patients With Reconstruction. International Journal of Radiation Oncology Biology Physics, 2022, 112, 445-456.	0.8	9
3	Diagnostic performance improvement with combined use of proteomics biomarker assay and breast ultrasound. Breast Cancer Research and Treatment, 2022, 192, 541-552.	2.5	2
4	The Usefulness of Ultrasound Surveillance for Axillary Recurrence in Women With Personal History of Breast Cancer. Journal of Breast Cancer, 2022, 25, 25.	1.9	2
5	Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-β pathway. Cancer Gene Therapy, 2022, 29, 1168-1180.	4.6	8
6	Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. Cancer Research, 2022, 82, PD15-08-PD15-08.	0.9	3
7	No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial. BMC Cancer, 2022, 22, 189.	2.6	15
8	Abstract P2-11-07: Mammographic density is associated with increased risk of contralateral breast cancers but not of ipsilateral breast tumor recurrences. Cancer Research, 2022, 82, P2-11-07-P2-11-07.	0.9	0
9	Abstract P3-18-12: Achieving negative margin after repeated attempts for lumpectomy does not nullify the risk of ipsilateral breast tumor recurrences. Cancer Research, 2022, 82, P3-18-12-P3-18-12.	0.9	0
10	Abstract P2-10-07: Prediction of menstruation recovery timing in premenopausal breast cancer patients taking tamoxifen after chemotherapy: An ASTRRA substudy. Cancer Research, 2022, 82, P2-10-07-P2-10-07.	0.9	0
11	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Medicine, 2022, 20, 105.	5.5	60
12	Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genetics in Medicine, 2022, 24, 586-600.	2.4	27
13	Peptidylâ€prolyl <i>cisâ€ŧrans</i> isomerase NIMAâ€interacting 1 directly binds and stabilizes Nrf2 in breast cancer. FASEB Journal, 2022, 36, e22068.	0.5	7
14	Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer. Oncogene, 2022, 41, 3151-3161.	5.9	7
15	Spatial epitranscriptomics reveals A-to-I editome specific to cancer stem cell microniches. Nature Communications, 2022, 13, 2540.	12.8	15
16	Effect of neoadjuvant versus adjuvant chemotherapy on ipsilateral breast tumor recurrence after breast-conserving surgery and whole-breast irradiation Journal of Clinical Oncology, 2022, 40, 604-604.	1.6	0
17	Abstract 6241: Macc1 regulates breast cancer progression and metastasis via remodeling tumor immune microenvironment. Cancer Research, 2022, 82, 6241-6241.	0.9	0
18	A randomized, prospective, multicenter trial of 3D printing, a patient-specific surgical guide for breast-conserving surgery after neoadjuvant chemotherapy: Comparative evaluation according to the presence or absence of surgical guide Journal of Clinical Oncology, 2022, 40, 576-576.	1.6	2

#	Article	IF	CITATIONS
19	The percentage of unnecessary mastectomy due to false size prediction by preoperative imaging studies in patients with breast cancer who underwent neoadjuvant chemotherapy Journal of Clinical Oncology, 2022, 40, 573-573.	1.6	1
20	A nomogram for predicting three or more axillary lymph node involvement before breast cancer surgery. Scientific Reports, 2022, 12, .	3.3	2
21	Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression: Implications for breast cancer progression. Cancer Letters, 2021, 500, 147-160.	7.2	17
22	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. European Journal of Cancer, 2021, 143, 134-146.	2.8	44
23	Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). Journal of Breast Cancer, 2021, 24, 164.	1.9	2
24	Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients. Cancer Research and Treatment, 2021, 53, 65-76.	3.0	8
25	Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics. Advances in Experimental Medicine and Biology, 2021, 1187, 215-244.	1.6	0
26	S100A8/A9 mediate the reprograming of normal mammary epithelial cells induced by dynamic cell–cell interactions with adjacent breast cancer cells. Scientific Reports, 2021, 11, 1337.	3.3	15
27	Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery. Journal of Breast Cancer, 2021, 24, 301.	1.9	4
28	Correlation between bone mineral density and endometrial thickness over time in women with breast cancer history. Science Progress, 2021, 104, 003685042110005.	1.9	0
29	Fusion Genes in Breast Cancer. Advances in Experimental Medicine and Biology, 2021, 1187, 147-157.	1.6	0
30	ls mastectomy with immediate reconstruction safe for patients undergoing neoadjuvant chemotherapy? A nationwide study from Korean Breast Cancer Society. Breast Cancer, 2021, 28, 874-883.	2.9	3
31	Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis. Breast, 2021, 55, 37-44.	2.2	19
32	15-Deoxy-Δ12,14-prostaglandin J2 Upregulates VEGF Expression via NRF2 and Heme Oxygenase-1 in Human Breast Cancer Cells. Cells, 2021, 10, 526.	4.1	11
33	The Emotional Status, Attitudes in Decision-Making Process, and Their Impact on Surgical Choices in Korean Breast Cancer Patients. Journal of Oncology, 2021, 2021, 1-6.	1.3	0
34	Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study. Scientific Reports, 2021, 11, 8485.	3.3	7
35	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. Cancers, 2021, 13, 2370.	3.7	4
36	Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report. European Journal of Cancer, 2021, 151, 190-200.	2.8	8

#	Article	IF	CITATIONS
37	Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 608207.	2.8	1
38	Interval Cancers after Negative Supplemental Screening Breast MRI Results in Women with a Personal History of Breast Cancer. Radiology, 2021, 300, 314-323.	7.3	12
39	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 741120.	2.8	2
40	Application of immunotherapy based on dendritic cells stimulated by tumor cell-derived exosomes in a syngeneic breast tumor mouse model. Biochemistry and Biophysics Reports, 2021, 28, 101136.	1.3	2
41	Next-Generation Sequencing-Based Biomarkers in Breast Cancer. Advances in Experimental Medicine and Biology, 2021, 1187, 323-335.	1.6	2
42	Multigene Panel Testing for Hereditary Cancer and Genetic Counseling. Advances in Experimental Medicine and Biology, 2021, 1187, 455-471.	1.6	2
43	Association between Number of Retrieved Sentinel Lymph Nodes and Breast Cancer-related Lymphedema. Journal of Breast Cancer, 2021, 24, 63.	1.9	10
44	STAT3 Stabilizes IKKα Protein through Direct Interaction in Transformed and Cancerous Human Breast Epithelial Cells. Cancers, 2021, 13, 82.	3.7	11
45	Comparison of Long-Term Oncological Outcomes in Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery for Breast Cancer: A Propensity Score-Matched Analysis. Journal of Breast Cancer, 2021, 24, 520.	1.9	3
46	Nearâ€infrared imageâ€guided laparoscopic omental flap for breast cancer. Asian Journal of Endoscopic Surgery, 2020, 13, 250-255.	0.9	2
47	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology, 2020, 38, 434-443.	1.6	52
48	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer. Clinical Breast Cancer, 2020, 20, 98-107.e1.	2.4	15
49	Development and Validation of a Next-Generation Sequencing–Based Multigene Assay to Predict the Prognosis of Estrogen Receptor–Positive, HER2-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 6513-6522.	7.0	6
50	Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59Âat diagnosis: A nationwide study. Breast, 2020, 53, 125-129.	2.2	7
51	Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages. Neoplasia, 2020, 22, 606-616.	5.3	15
52	Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer. Oncogenesis, 2020, 9, 91.	4.9	16
53	Accuracy of Post–Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surgery, 2020, 155, e204103.	4.3	58
54	Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. Breast, 2020, 54, 25-30.	2.2	11

#	Article	IF	CITATIONS
55	Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. Breast Cancer Research and Treatment, 2020, 182, 97-105.	2.5	36
56	Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages. Cell Reports, 2020, 31, 107643.	6.4	16
57	NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis. BMC Cancer, 2020, 20, 375.	2.6	11
58	Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Research, 2020, 22, 54.	5.0	32
59	A Nomogram for Predicting Three or More Axillary Lymph Node Involvement before Breast Cancer Surgery. European Journal of Surgical Oncology, 2020, 46, e51-e52.	1.0	0
60	<i>BRAF^{V600E}</i> Transduction of an SV40-Immortalized Normal Human Thyroid Cell Line Induces Dedifferentiated Thyroid Carcinogenesis in a Mouse Xenograft Model. Thyroid, 2020, 30, 487-500.	4.5	5
61	H-Ras induces Nrf2-Pin1 interaction: Implications for breast cancer progression. Toxicology and Applied Pharmacology, 2020, 402, 115121.	2.8	5
62	OPENchip: an on-chip <i>in situ</i> molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells. Lab on A Chip, 2020, 20, 912-922.	6.0	14
63	Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching. BMC Cancer, 2020, 20, 78.	2.6	15
64	Recurrence at the Nipple-Areola Complex and Safety of Nipple-Sparing Mastectomy. JAMA Surgery, 2020, 155, 364.	4.3	1
65	Efficacy of health coaching and a webâ€based program on physical activity, weight, and distress management among cancer survivors: A multiâ€centered randomised controlled trial. Psycho-Oncology, 2020, 29, 1105-1114.	2.3	28
66	Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis. , 2020, , .		10
67	Personalized neoadjuvant strategy in luminal A breast cancer to increase breast conserving surgery (BCS) rate [PLATO study] Journal of Clinical Oncology, 2020, 38, TPS603-TPS603.	1.6	5
68	A Review of the Epidemiology of Breast Cancer in Asia: Focus on Risk Factors. Asian Pacific Journal of Cancer Prevention, 2020, 21, 867-880.	1.2	65
69	Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers. Journal of Breast Cancer, 2020, 23, 162.	1.9	5
70	Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients. Journal of Breast Cancer, 2020, 23, 182.	1.9	12
71	Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test. Cancer Research and Treatment, 2020, 52, 697-713.	3.0	28
72	Abstract P3-08-37: Dynamic and subtype-specific interactions between tumor burden and prognosis in breast cancer. , 2020, , .		0

#	Article	IF	CITATIONS
73	Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer. Journal of Breast Cancer, 2020, 23, 268.	1.9	1
74	lmmune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage l–III breast cancer patients. British Journal of Cancer, 2019, 121, 230-236.	6.4	14
75	Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis. Breast Cancer Research and Treatment, 2019, 178, 185-197.	2.5	7
76	Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI. Magnetic Resonance Imaging, 2019, 63, 60-69.	1.8	14
77	Prognostic effects of abnormal DNA damage response protein expression in breast cancer. Breast Cancer Research and Treatment, 2019, 175, 117-127.	2.5	8
78	Whole Genome Sequencing of Single Circulating Tumor Cells Isolated by Applying a Pulsed Laser to Cell apturing Microstructures. Small, 2019, 15, e1902607.	10.0	26
79	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. Journal of the National Cancer Institute, 2019, 111, 1298-1306.	6.3	83
80	miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer. Cancer Letters, 2019, 454, 224-233.	7.2	59
81	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. Breast Cancer Research and Treatment, 2019, 176, 453-460.	2.5	9
82	Total Intravenous Anesthesia <i>versus</i> Inhalation Anesthesia for Breast Cancer Surgery. Anesthesiology, 2019, 130, 31-40.	2.5	110
83	Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. Cancer Research, 2019, 79, 1520-1534.	0.9	126
84	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. Breast Cancer Research and Treatment, 2019, 175, 203-215.	2.5	13
85	Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer. Oncologist, 2019, 24, e1268-e1276.	3.7	10
86	Risk Factors for Recurrence of Malignant Phyllodes Tumors of the Breast. In Vivo, 2019, 33, 263-269.	1.3	12
87	Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. Journal of Oncology, 2019, 2019, 1-8.	1.3	11
88	Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1475-1479.	1.2	4
89	Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy. Journal of Breast Cancer, 2019, 22, 624.	1.9	6
90	A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer. Journal of Breast Cancer, 2019, 22, 579.	1.9	11

#	Article	IF	CITATIONS
91	Mastocheck: Notable plasma protein biomarker for diagnosis of breast cancer in the real clinical practice by using multiple reaction monitoring-based mass spectrometry Journal of Clinical Oncology, 2019, 37, 3044-3044.	1.6	1
92	Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study] Journal of Clinical Oncology, 2019, 37, 576-576.	1.6	6
93	Abstract 4914: Pregnancy and breast cancer outcomes. , 2019, , .		0
94	Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS). Pharmacogenomics Journal, 2018, 18, 633-645.	2.0	10
95	Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour. European Radiology, 2018, 28, 2986-2995.	4.5	31
96	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. Clinical Breast Cancer, 2018, 18, e1165-e1172.	2.4	1
97	Association between US features of primary tumor and axillary lymph node metastasis in patients with clinical T1–T2N0 breast cancer. Acta Radiologica, 2018, 59, 402-408.	1.1	30
98	Management of benign papilloma without atypia diagnosed at ultrasound-guided core needle biopsy: Scoring system for predicting malignancy. European Journal of Surgical Oncology, 2018, 44, 53-58.	1.0	36
99	Development and validation of the smart management strategy for health assessment tool-short form (SAT-SF) in cancer survivors. Quality of Life Research, 2018, 27, 347-354.	3.1	8
100	Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. Translational Oncology, 2018, 11, 18-23.	3.7	26
101	Association of preoperative breast MRI features with locoregional recurrence after breast conservation therapy. Acta Radiologica, 2018, 59, 409-417.	1.1	9
102	PHLI-seq: constructing and visualizing cancer genomic maps in 3D by phenotype-based high-throughput laser-aided isolation and sequencing. Genome Biology, 2018, 19, 158.	8.8	18
103	Prognostic influence of 3-dimensional tumor volume on breast cancer compared to conventional 1-dimensional tumor size. Annals of Surgical Treatment and Research, 2018, 95, 183.	1.0	6
104	Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis. Journal of Breast Cancer, 2018, 21, 37.	1.9	6
105	Perspective Insight into Future Potential Fusion Gene Transcript Biomarker Candidates in Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 502.	4.1	17
106	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study Journal of Clinical Oncology, 2018, 36, 502-502.	1.6	14
107	Prediction of pathologic complete response by image-guided biopsy before surgery in breast cancer with complete clinical response to neoadjuvant chemotherapy: A prospective feasibility trial Journal of Clinical Oncology, 2018, 36, 566-566.	1.6	3
108	Abstract 1166: Identification of predictive markers for clinical efficacy of triple-negative breast cancer chemotherapy. , 2018, , .		0

#	Article	IF	CITATIONS
109	Perceived needs for the information communication technology (ICT)â€based personalized health management program, and its association with information provision, healthâ€related quality of life (HRQOL), and decisional conflict in cancer patients. Psycho-Oncology, 2017, 26, 1810-1817.	2.3	9

Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG) Tj ETQq0 0 0 gBT /Over4ock 10 Tf 110

111	Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporosis International, 2017, 28, 1413-1422.	3.1	32
112	Who are happy survivors? Physical, psychosocial, and spiritual factors associated with happiness of breast cancer survivors during the transition from cancer patient to survivor. Psycho-Oncology, 2017, 26, 1922-1928.	2.3	27
113	Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society. Medical Oncology, 2017, 34, 118.	2.5	8
114	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nature Communications, 2017, 8, 15081.	12.8	743
115	Opportunistic Biopsy of Internal Mammary Lymph Nodes During Immediate Breast Reconstruction After Mastectomy for Breast Malignancies. Annals of Surgical Oncology, 2017, 24, 1881-1888.	1.5	7
116	Gene expression profiling of calcifications in breast cancer. Scientific Reports, 2017, 7, 11427.	3.3	21
117	Post-clip placement MRI following second-look US-guided core biopsy for suspicious lesions identified on breast MRI. European Radiology, 2017, 27, 5196-5203.	4.5	6
118	Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2017, 166, 473-480.	2.5	32
119	Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy. JAMA Oncology, 2017, 3, 1495.	7.1	112
120	An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment. BMC Cancer, 2017, 17, 389.	2.6	3
121	Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget, 2017, 8, 93117-93130.	1.8	28
122	The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are <i>BRCA</i> Mutation Carrier. Journal of Breast Cancer, 2017, 20, 279.	1.9	2
123	Feature of amenorrhea in postoperative tamoxifen users with breast cancer. Journal of Gynecologic Oncology, 2017, 28, e10.	2.2	9
124	Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer. Journal of Breast Cancer, 2017, 20, 54.	1.9	19
125	Genetic Predisposition of Polymorphisms inHMGB1-Related Genes to Breast Cancer Prognosis in Korean Women. Journal of Breast Cancer, 2017, 20, 27.	1.9	7
126	Reproductive factors as risk modifiers of breast cancer in <i>BRCA</i> mutation carriers and high-risk non-carriers. Oncotarget, 2017, 8, 102110-102118.	1.8	23

#	Article	IF	CITATIONS
127	Time interval of neoadjuvant chemotherapy to surgery in breast cancer: how long is acceptable?. Gland Surgery, 2017, 6, 1-3.	1.1	7
128	Survival outcomes of screening with breast MRI in high-risk women Journal of Clinical Oncology, 2017, 35, 1508-1508.	1.6	5
129	A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012) Journal of Clinical Oncology, 2017, 35, 517-517.	1.6	1
130	Frequency of germline patghogenic mutation in breast cancer patients at high risk hereditary cancer Journal of Clinical Oncology, 2017, 35, e13110-e13110.	1.6	1
131	Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism. PLoS ONE, 2017, 12, e0174126.	2.5	47
132	Risk Reduction of Breast Cancer by Childbirth, Breastfeeding, and Their Interaction in Korean Women: Heterogeneous Effects Across Menopausal Status, Hormone Receptor Status, and Pathological Subtypes. Journal of Preventive Medicine and Public Health, 2017, 50, 401-410.	1.9	14
133	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea. Cancer Research and Treatment, 2017, 49, 454-463.	3.0	1
134	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. Cancer Research and Treatment, 2017, 49, 1153-1163.	3.0	9
135	Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery. Cancer Research and Treatment, 2017, 49, 1088-1096.	3.0	24
136	The treatment outcomes and the use of adjuvant therapies in breast cancer patients with severe co-morbidities. PLoS ONE, 2017, 12, e0173721.	2.5	4
137	Abstract 4739: Prognostic impact of abnormal DNA damage response protein expression in breast cancer. , 2017, , .		0
138	Abstract 4786: Integrated eoxme and transcriptome sequencing identifies a novel candidate for breast cancer. , 2017, , .		0
139	Abstract 1276: Gene-environment interaction relevant to estrogen and risk of breast cancer. , 2017, , .		0
140	Actual Conversion Rate from Total Mastectomy to Breast Conservation after Neoadjuvant Chemotherapy for Stages II–III Breast Cancer Patients. Journal of Breast Disease, 2017, 5, 51-56.	0.2	3
141	Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. Journal of Breast Cancer, 2016, 19, 268.	1.9	5
142	Oncologic Safety of Immediate Breast Reconstruction for Invasive Breast Cancer Patients: A Matched Case Control Study. Journal of Breast Cancer, 2016, 19, 68.	1.9	37
143	Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer. PLoS ONE, 2016, 11, e0158461.	2.5	17
144	Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy. Journal of Breast Cancer, 2016, 19, 394.	1.9	5

#	Article	IF	CITATIONS
145	Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea. Medicine (United States), 2016, 95, e3063.	1.0	15
146	A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer. Medicine (United States), 2016, 95, e3320.	1.0	4
147	The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. BMC Cancer, 2016, 16, 319.	2.6	19
148	Enhancement of Capture Sensitivity for Circulating Tumor Cells in a Breast Cancer Patient's Blood by Silicon Nanowire Platform. Journal of Biomedical Nanotechnology, 2016, 12, 645-655.	1.1	4
149	Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. BMC Cancer, 2016, 16, 430.	2.6	15
150	Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 183-190.	2.8	38
151	Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. European Journal of Surgical Oncology, 2016, 42, 1169-1175.	1.0	5
152	Information theoretic sub-network mining characterizes breast cancer subtypes in terms of cancer core mechanisms. Journal of Bioinformatics and Computational Biology, 2016, 14, 1644002.	0.8	2
153	Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1574-1584.	6.4	10
154	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. BMC Cancer, 2016, 16, 515.	2.6	11
155	Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discovery, 2016, 2, 16025.	6.7	77
156	The Spatial Relationship of Malignant and Benign Breast Lesions with Respect to the Fat-Gland Interface on Magnetic Resonance Imaging. Scientific Reports, 2016, 6, 39085.	3.3	10
157	Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine (United States), 2016, 95, e4874.	1.0	42
158	Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival. Radiology, 2016, 281, 392-400.	7.3	100
159	Reliability of Computer-Assisted Breast Density Estimation: Comparison of Interactive Thresholding, Semiautomated, and Fully Automated Methods. American Journal of Roentgenology, 2016, 207, 126-134.	2.2	5
160	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2016, 158, 233-241.	2.5	10
161	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2016, 142, 707-714.	2.5	8
162	Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer. Clinical and Experimental Metastasis, 2016, 33, 179-185.	3.3	36

#	Article	IF	CITATIONS
163	New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer. Tumor Biology, 2016, 37, 11017-11024.	1.8	20
164	Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence. Radiology, 2016, 278, 356-364.	7.3	42
165	Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget, 2016, 7, 38500-38512.	1.8	24
166	Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane. Cancer Research and Treatment, 2016, 48, 483-490.	3.0	12
167	Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer. Cancer Research and Treatment, 2016, 48, 962-969.	3.0	30
168	Nomograms to Predict Positive Resection Margin and to Predict Three or More Positive Lymph Nodes. , 2016, , 335-345.		0
169	Clinical significance of axillary lymph node count in axillary dissection following neoadjuvant chemotherapy for breast cancer Journal of Clinical Oncology, 2016, 34, e12508-e12508.	1.6	Ο
170	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer Journal of Clinical Oncology, 2016, 34, e23268-e23268.	1.6	0
171	Clinical implication of internal mammary lymph node biopsy during immediate breast reconstruction using autologous tissue free flaps in breast cancer surgery Journal of Clinical Oncology, 2016, 34, 1064-1064.	1.6	0
172	The association between patient comorbidity and breast cancer survival Journal of Clinical Oncology, 2016, 34, e12047-e12047.	1.6	0
173	Oncological safety of oncoplastic breast conserving surgery-compare with conventional breast conserving surgery and total mastectomy Journal of Clinical Oncology, 2016, 34, e12531-e12531.	1.6	Ο
174	Abstract 160: Identification of the carcinoma and immune cells in the breast cancer by single-cell RNA sequencing. , 2016, , .		0
175	Abstract 161: Single-cell RNA sequencing presents explicit expression signatures in primary breast cancer. , 2016, , .		0
176	Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features. Oncotarget, 2016, 7, 81888-81898.	1.8	1
177	Reduced proliferation in breast cancer cells contacting the neighboring adipocytes in human breast cancer tissues. Breast Cancer Research, 2015, 17, 90.	5.0	4
178	Recurrent fusion transcripts detected by wholeâ€ŧranscriptome sequencing of 120 primary breast cancer samples. Genes Chromosomes and Cancer, 2015, 54, 681-691.	2.8	38
179	The use of FNA samples for wholeâ€exome sequencing and detection of somatic mutations in breast cancer surgical specimens. Cancer Cytopathology, 2015, 123, 669-677.	2.4	11
180	Patientâ€reported assessment of selfâ€management strategies of health in cancer patients: development and validation of the Smart Management Strategy for Health Assessment Tool (SAT). Psycho-Oncology, 2015, 24, 1723-1730.	2.3	24

#	Article	IF	CITATIONS
181	Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study. Journal of Breast Cancer, 2015, 18, 8.	1.9	12
182	Risk Factors Associated with Distant Metastasis and Survival Outcomes in Breast Cancer Patients with Locoregional Recurrence. Journal of Breast Cancer, 2015, 18, 160.	1.9	24
183	Prediction of Breast Cancer Survival Using Clinical and Genetic Markers by Tumor Subtypes. PLoS ONE, 2015, 10, e0122413.	2.5	14
184	Tumor Subtype-Specific Associations of Hormone-Related Reproductive Factors on Breast Cancer Survival. PLoS ONE, 2015, 10, e0123994.	2.5	17
185	In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients. PLoS ONE, 2015, 10, e0144144.	2.5	19
186	Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy. Cancer Research and Treatment, 2015, 47, 197-207.	3.0	8
187	Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. European Radiology, 2015, 25, 3314-3321.	4.5	34
188	Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer, 2015, 18, 16.	1.9	38
189	Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Human Pathology, 2015, 46, 1027-1035.	2.0	47
190	Effect of cosmetic outcome on quality of life after breast cancer surgery. European Journal of Surgical Oncology, 2015, 41, 426-432.	1.0	184
191	A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. Human Pathology, 2015, 46, 246-254.	2.0	9
192	Drug response of captured BT20 cells and evaluation of circulating tumor cells on a silicon nanowire platform. Biosensors and Bioelectronics, 2015, 67, 370-378.	10.1	10
193	Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression. European Radiology, 2015, 25, 419-427.	4.5	23
194	The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Research and Treatment, 2015, 151, 157-168.	2.5	82
195	Reappraisal of Conventional Risk Stratification for Local Recurrence Based on Clinical Outcomes in 285 Resected Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2015, 22, 2912-2918.	1.5	61
196	The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. Annals of Surgical Oncology, 2015, 22, 3481-3488.	1.5	20
197	Breast Cancer: Radiogenomic Biomarker Reveals Associations among Dynamic Contrast-enhanced MR Imaging, Long Noncoding RNA, and Metastasis. Radiology, 2015, 275, 384-392.	7.3	111
198	Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology, 2015, 22, 391-397.	1.5	1

#	Article	IF	CITATIONS
199	A Possible Association Between Thyroid Cancer and Breast Cancer. Thyroid, 2015, 25, 1330-1338.	4.5	57
200	Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers. Breast Cancer Research and Treatment, 2015, 154, 13-22.	2.5	62
201	Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. Breast Cancer Research and Treatment, 2015, 153, 361-370.	2.5	17
202	Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology, 2015, 11, 1301-1305.	2.4	3
203	Breast Cancer Recurrence in Patients with Newly Diagnosed Breast Cancer without and with Preoperative MR Imaging: A Matched Cohort Study. Radiology, 2015, 276, 695-705.	7.3	36
204	Association between information provision and decisional conflict in cancer patients. Annals of Oncology, 2015, 26, 1974-1980.	1.2	21
205	Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 563-570.	2.8	23
206	Shear-Wave Elastography for the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2015, 22, 376-384.	1.5	25
207	<i><scp>ABCB</scp>1</i> polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Science, 2015, 106, 86-93.	3.9	59
208	Ultrasound screening of contralateral breast after surgery for breast cancer. European Journal of Radiology, 2015, 84, 54-60.	2.6	14
209	Location of Triple-Negative Breast Cancers: Comparison with Estrogen Receptor-Positive Breast Cancers on MR Imaging. PLoS ONE, 2015, 10, e0116344.	2.5	9
210	The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers. PLoS ONE, 2015, 10, e0143811.	2.5	15
211	The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea. Cancer Research and Treatment, 2015, 47, 208-214.	3.0	23
212	Breast Cancer: Serum TPS as a Biomarker. Biomarkers in Disease, 2015, , 417-427.	0.1	1
213	Abstract P1-12-07: Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years. , 2015, , .		Ο
214	Abstract P2-05-07: Feasibility and sensitivity of fine-needle aspiration biopsies for the detection of somatic mutations using next-generation sequencing in breast cancer. , 2015, , .		0
215	Abstract P5-10-10: Effect of prolonged cold ischemic time on immunohistochemical testing of estrogen receptor, progesterone receptor and HER2 expression in breast cancer. , 2015, , .		0
216	Abstract P1-12-13: Factors associated with adherence to adjuvant endocrine therapy in patients with hormone receptor positive breast cancer. , 2015, , .		0

#	Article	IF	CITATIONS
217	Abstract P2-03-10: Comprehensive somatic SNV and CNV profiling for triple-negative breast cancer patients by targeted next-generation sequencing. , 2015, , .		0
218	Prognostic effect of PgR in luminal type breast cancer Journal of Clinical Oncology, 2015, 33, e11566-e11566.	1.6	0
219	Abstract 3372: Molecular characteristics of cancer-associated adipocytes in breast cancer. , 2015, , .		0
220	Abstract A2-08: Lymph node metastasis-related genes discovered through patient-derived xenograft models. , 2015, , .		0
221	The Effect of Cold Ischemic Time on Immunohistochemical Evaluation of Invasive Ductal Carcinoma. Journal of Breast Disease, 2015, 3, 60-64.	0.2	Ο
222	The Roles of Modern Breast Imaging Techniques for Evaluation of Lobular Carcinoma <i>In Situ</i> of the Breast. Journal of Breast Disease, 2015, 3, 71-76.	0.2	1
223	Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry. Anticancer Research, 2015, 35, 6271-9.	1.1	17
224	Unique Features of Young Age Breast Cancer and Its Management. Journal of Breast Cancer, 2014, 17, 301.	1.9	92
225	Low Rates of Additional Cancer Detection by Magnetic Resonance Imaging in Newly Diagnosed Breast Cancer Patients Who Undergo Preoperative Mammography and Ultrasonography. Journal of Breast Cancer, 2014, 17, 167.	1.9	15
226	Breast Cancer: Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response Maps for MR Imaging. Radiology, 2014, 272, 385-396.	7.3	81
227	Breast MR Imaging Screening in Women with a History of Breast Conservation Therapy. Radiology, 2014, 272, 366-373.	7.3	81
228	Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: A case-case study. International Journal of Cancer, 2014, 135, 669-681.	5.1	14
229	Breast Cancer: Serum TPS as a Biomarker. , 2014, , 1-9.		Ο
230	Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer, 2014, 14, 170.	2.6	54
231	Shear-Wave Elastographic Features of Breast Cancers. Investigative Radiology, 2014, 49, 147-155.	6.2	39
232	Effect of Axillary Lymph Node Dissection after Sentinel Lymph Node Biopsy on Overall Survival in Patients with T1 or T2 Node-positive Breast Cancer: Report from the Korean Breast Cancer Society. Annals of Surgical Oncology, 2014, 21, 1231-1236.	1.5	21
233	Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers. Oncology, 2014, 86, 279-288.	1.9	6
234	The Associations between Immunity-Related Genes and Breast Cancer Prognosis in Korean Women. PLoS ONE, 2014, 9, e103593.	2.5	17

#	Article	IF	CITATIONS
235	Treatment outcome of ductal carcinoma <i>in situ</i> patients treated with postoperative radiation therapy. Radiation Oncology Journal, 2014, 32, 1.	1.5	3
236	Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review. Cancer Research and Treatment, 2014, 46, 93-97.	3.0	32
237	A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions. Cancer Research and Treatment, 2014, 46, 280-287.	3.0	2
238	Serum Adiponectin but not Leptin at Diagnosis as a Predictor of Breast Cancer Survival. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6137-6143.	1.2	13
239	Effect of prolonged cold ischemic time on immunohistochemical testing of estrogen receptor, progesterone receptor, and HER2 expression in breast cancer Journal of Clinical Oncology, 2014, 32, e11505-e11505.	1.6	2
240	Factors associated with adherence to adjuvant endocrine therapy in patients with hormone receptor positive breast cancer Journal of Clinical Oncology, 2014, 32, e11502-e11502.	1.6	0
241	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy Journal of Clinical Oncology, 2014, 32, 1038-1038.	1.6	0
242	Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast Journal of Clinical Oncology, 2014, 32, e22217-e22217.	1.6	1
243	Abstract 3273: Genetic variation in obesity-related genes and breast cancer risk in the Seoul Breast Cancer Study. , 2014, , .		0
244	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Research, 2014, 34, 4275-80.	1.1	7
245	Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. Breast Cancer, 2013, 20, 167-173.	2.9	17
246	Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer Patients. Annals of Surgical Oncology, 2013, 20, 2582-2589.	1.5	51
247	Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study. Breast Cancer Research and Treatment, 2013, 140, 557-565.	2.5	27
248	Association of Tumour Stiffness on Sonoelastography with Axillary Nodal Status in T1 Breast Carcinoma Patients. European Radiology, 2013, 23, 2979-2987.	4.5	21
249	Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status. European Radiology, 2013, 23, 2072-2078.	4.5	28
250	Impact of genetic polymorphisms in base excision repair genes on the risk of breast cancer in a Korean population. Gene, 2013, 532, 192-196.	2.2	20
251	Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society. Annals of Oncology, 2013, 24, 2298-2304.	1.2	15
252	Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer, 2013, 13, 503.	2.6	24

#	Article	IF	CITATIONS
253	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgical Oncology, 2013, 20, 2242-2249.	1.5	12
254	Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer. Gynecological Endocrinology, 2013, 29, 16-19.	1.7	5
255	Grade of Ductal Carcinoma In Situ Accompanying Infiltrating Ductal Carcinoma As an Independent Prognostic Factor. Clinical Breast Cancer, 2013, 13, 385-391.	2.4	16
256	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Human Molecular Genetics, 2013, 22, 2539-2550.	2.9	86
257	The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study. Familial Cancer, 2013, 12, 75-81.	1.9	43
258	Preoperative serum tissue polypeptideâ€specific antigen is a valuable prognostic marker in breast cancer. International Journal of Cancer, 2013, 132, 875-881.	5.1	22
259	Patient Age and Tumor Size Determine the Cancer Yield of Preoperative Bilateral Breast MRI in Women With Ductal Carcinoma In Situ. American Journal of Roentgenology, 2013, 201, 684-691.	2.2	10
260	Unilateral Breast Cancer: Screening of Contralateral Breast by Using Preoperative MR Imaging Reduces Incidence of Metachronous Cancer. Radiology, 2013, 267, 57-66.	7.3	56
261	New Breast Cancer Risk Variant Discovered at 10q25 in East Asian Women. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1297-1303.	2.5	5
262	Survival Outcomes of Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy: Association with Dynamic Contrast-enhanced MR Imaging with Computer-aided Evaluation. Radiology, 2013, 268, 662-672.	7.3	47
263	STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells. Molecular Cancer Research, 2013, 11, 31-42.	3.4	67
264	Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines. International Journal of Oncology, 2013, 43, 2073-2081.	3.3	6
265	Breast Cancer Molecular Phenotype and the Use of HER2-Targeted Agents Influence the Accuracy of Breast MRI After Neoadjuvant Chemotherapy. Annals of Surgery, 2013, 257, 133-137.	4.2	35
266	Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors. Journal of Breast Cancer, 2013, 16, 66.	1.9	4
267	Leptin as a Potential Target for Estrogen Receptor-Positive Breast Cancer. Journal of Breast Cancer, 2013, 16, 138.	1.9	22
268	Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer. Journal of Breast Cancer, 2013, 16, 386.	1.9	8
269	Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer, 2013, 16, 378.	1.9	27
270	Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response. Journal of Breast Cancer, 2013, 16, 395.	1.9	32

#	Article	IF	CITATIONS
271	FoxM1 as a potential therapeutic target for triple-negative breast cancer Journal of Clinical Oncology, 2013, 31, e22063-e22063.	1.6	1
272	Korean Risk Assessment Model for Breast Cancer Risk Prediction. PLoS ONE, 2013, 8, e76736.	2.5	44
273	Abstract 2550: A genome-wide association study of breast cancer survival according to molecular subtype in Korean women , 2013, , .		Ο
274	Abstract 128: Chronological changes of hormone receptor status in breast cancer by reproductive factors: results from Seoul Breast Cancer Study (SeBCS) , 2013, , .		0
275	Ki-67 level in hormone reptor positive breast cancer patients: A retrospective review of 9,061 Korean women Journal of Clinical Oncology, 2013, 31, 551-551.	1.6	5
276	Nomogram for predicting breast-conservation surgery after neoadjuvant chemotherapy Journal of Clinical Oncology, 2013, 31, 1128-1128.	1.6	0
277	Personalized treatment in breast cancer. Korean Journal of Clinical Oncology, 2013, 9, 1-4.	0.1	0
278	Abstract A014: A clinically relevant prognostic mRNA signature for triple-negative breast cancer developed from the patient-derived xenograft model. , 2013, , .		0
279	ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy. Oncology, 2012, 83, 218-227.	1.9	23
280	A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Research, 2012, 14, R56.	5.0	118
281	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research, 2012, 14, R102.	5.0	86
282	Nomogram for predicting positive resection margins after breast-conserving surgery. Breast Cancer Research and Treatment, 2012, 134, 1115-1123.	2.5	42
283	Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy. Breast Cancer Research and Treatment, 2012, 134, 1133-1140.	2.5	13
284	Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research and Treatment, 2012, 136, 919-926.	2.5	5
285	Limited Value and Utility of Breast MRI in Patients Undergoing Breast-Conserving Cancer Surgery. Annals of Surgical Oncology, 2012, 19, 2572-2579.	1.5	51
286	BRCA2 Fine-Tunes the Spindle Assembly Checkpoint through Reinforcement of BubR1 Acetylation. Developmental Cell, 2012, 22, 295-308.	7.0	71
287	Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients. European Journal of Radiology, 2012, 81, 737-743.	2.6	13
288	Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer. BMC Cancer, 2012, 12, 585.	2.6	10

#	Article	IF	CITATIONS
289	Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. BMC Medical Informatics and Decision Making, 2012, 12, 54.	3.0	36
290	Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast, 2012, 21, 641-645.	2.2	63
291	Evaluation of tumor extent in breast cancer patients using real-time MR navigated ultrasound: Preliminary study. European Journal of Radiology, 2012, 81, 3208-3215.	2.6	21
292	Outcome of breast lesions detected at screening ultrasonography. European Journal of Radiology, 2012, 81, 3229-3233.	2.6	15
293	Present Condition Analysis of Physician Assistant in Korea. Journal of Korean Medical Science, 2012, 27, 981.	2.5	4
294	Validation of a Scoring System for Predicting Malignancy in Patients Diagnosed with Atypical Ductal Hyperplasia Using an Ultrasound-Guided Core Needle Biopsy. Journal of Breast Cancer, 2012, 15, 407.	1.9	13
295	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. Journal of Breast Cancer, 2012, 15, 427.	1.9	15
296	Prognostic influence of BCL2 expression in breast cancer. International Journal of Cancer, 2012, 131, E1109-19.	5.1	50
297	Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. European Radiology, 2012, 22, 18-25.	4.5	91
298	Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. Breast, 2012, 21, 66-71.	2.2	72
299	SNP–SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population. Cancer, 2012, 118, 594-602.	4.1	34
300	COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Research and Treatment, 2012, 132, 51-59.	2.5	52
301	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. Journal of Neuro-Oncology, 2012, 106, 303-313.	2.9	64
302	The role and significance of FoxM1 in invasive breast cancer Journal of Clinical Oncology, 2012, 30, 1056-1056.	1.6	0
303	Scoring system for prediction of having three or more involved axillary nodes for breast cancer Journal of Clinical Oncology, 2012, 30, 1133-1133.	1.6	0
304	Identification and validation of plasma protein biomarker panels for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry Journal of Clinical Oncology, 2012, 30, 10621-10621.	1.6	0
305	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in estrogen receptor-positive breast cancer Journal of Clinical Oncology, 2012, 30, e21160-e21160.	1.6	0
306	Breast-conserving surgery after neoadjuvant chemotherapy for stage III breast cancer patients Journal of Clinical Oncology, 2012, 30, e11532-e11532.	1.6	0

#	Article	IF	CITATIONS
307	Common Genetic Variants Associated with Breast Cancer in Korean Women and Differential Susceptibility According to Intrinsic Subtype. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 793-798.	2.5	68
308	NFIB is a potential target for estrogen receptorâ€negative breast cancers. Molecular Oncology, 2011, 5, 538-544.	4.6	54
309	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research, 2011, 13, R22.	5.0	187
310	Impact of delayed radiotherapy on local control in node-negative breast cancer patients treated with breast-conserving surgery and adjuvant radiotherapy without chemotherapy. Tumori, 2011, 97, 341-344.	1.1	9
311	Clinical Significance of Annexin A1 Expression in Breast Cancer. Journal of Breast Cancer, 2011, 14, 262.	1.9	63
312	17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy. Experimental and Therapeutic Medicine, 2011, 2, 799-804.	1.8	4
313	The Effectiveness of Silver <i>In Situ</i> Hybridization in Patients with Breast Cancer: A Systematic Review. Journal of Breast Cancer, 2011, 14, S1.	1.9	0
314	The CD49d+/high subpopulation from isolated human breast sarcoma spheres possesses tumor-initiating ability. International Journal of Oncology, 2011, 40, 665-72.	3.3	13
315	Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms. Cancer Science, 2011, 102, 1862-1867.	3.9	39
316	Age <40 Years is an Independent Prognostic Factor Predicting Inferior Overall Survival in Patients Treated with Breast Conservative Therapy. Breast Journal, 2011, 17, 75-78.	1.0	9
317	The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. Breast Cancer Research and Treatment, 2011, 126, 637-641.	2.5	46
318	Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Research and Treatment, 2011, 130, 499-505.	2.5	31
319	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1301-1308.	2.5	32
320	Prognostic Significance of Young Age (<35 Years) by Subtype Based on ER, PR, and HER2 Status in Breast Cancer: A Nationwide Registryâ€Based Study. World Journal of Surgery, 2011, 35, 1244-1253.	1.6	63
321	Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer, 2011, 11, 452.	2.6	61
322	Management of Ultrasonographically Detected Benign Papillomas of the Breast at Core Needle Biopsy. American Journal of Roentgenology, 2011, 196, 723-729.	2.2	58
323	A Serum Protein Profile Predictive of the Resistance to Neoadjuvant Chemotherapy in Advanced Breast Cancers. Molecular and Cellular Proteomics, 2011, 10, M111.011023.	3.8	42
324	Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Tumori, 2011, 97, 280-5.	1.1	5

#	Article	IF	CITATIONS
325	Impact of delayed radiotherapy on local control in node-negative breast cancer patients treated with breast-conserving surgery and adjuvant radiotherapy without chemotherapy. Tumori, 2011, 97, 341-4.	1.1	7
326	Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer. , 2010, 4, 53-77.		102
327	Prognostic Factors Affecting the Outcome of Salvage Radiotherapy for Isolated Locoregional Recurrence After Mastectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 23-27.	1.3	14
328	Characterization of molecular subtypes of Korean breast cancer: An ethnically and clinically distinct population. International Journal of Oncology, 2010, 37, 51-9.	3.3	0
329	Regularized multivariate regression for identifying master predictors with application to integrative genomics study of breast cancer. Annals of Applied Statistics, 2010, 4, .	1.1	183
330	Risk of carcinoma after subsequent excision of benign papilloma initially diagnosed with an ultrasound (US)-guided 14-gauge core needle biopsy: a prospective observational study. European Radiology, 2010, 20, 1093-1100.	4.5	63
331	Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35Âyears is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Research and Treatment, 2010, 119, 193-200.	2.5	129
332	The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine, 2010, 17, 436-440.	5.3	121
333	Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for korean women with breast cancer: Retrospective cohort study of the korean breast cancer society database. Clinical Therapeutics, 2010, 32, 1122-1138.	2.5	8
334	Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer, 2010, 116, 2890-2901.	4.1	53
335	Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene, 2010, 29, 774-779.	5.9	57
336	Clinicopathological Characteristics and Factors Affecting Recurrence of Ductal Carcinoma <i>In Situ</i> in Korean Women. Journal of Breast Cancer, 2010, 13, 392.	1.9	2
337	Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy. Journal of Korean Medical Science, 2010, 25, 235.	2.5	8
338	COL18A1 as the Candidate Gene for the Prognostic Marker of Breast Cancer According to the Analysis of the DNA Copy Number Variation by Array CGH. Journal of Breast Cancer, 2010, 13, 37.	1.9	3
339	The Impact of Primary Tumor Resection on the Survival of Patients with Stage IV Breast Cancer. Journal of Breast Cancer, 2010, 13, 90.	1.9	1
340	One-step Nucleic Acid Amplification (OSNA): Intraoperative Rapid Molecular Diagnostic Method for the Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients in Korean Cohort. Journal of Breast Cancer, 2010, 13, 366.	1.9	3
341	Limitations of Conventional Contrast-enhanced MRI in Selecting Sentinel Node Biopsy Candidates among DCIS Patients. Journal of Breast Cancer, 2010, 13, 154.	1.9	1
342	Comparable Survival Between pNO Breast Cancer Patients Undergoing Sentinel Node Biopsy and Extensive Axillary Dissection: A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology, 2010, 28, 1692-1699.	1.6	25

#	Article	IF	CITATIONS
343	Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity. Japanese Journal of Clinical Oncology, 2010, 40, 112-118.	1.3	41
344	Reply to MH. Tan et al. Journal of Clinical Oncology, 2010, 28, e178-e179.	1.6	0
345	Diffusion-weighted MR Imaging: Pretreatment Prediction of Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Radiology, 2010, 257, 56-63.	7.3	249
346	Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Human Molecular Genetics, 2010, 19, 4273-4277.	2.9	78
347	Efficacy of Breast Ultrasonography for Detection of Local, Regional, and Contralateral Recurrence of Breast Cancer. Journal of Breast Cancer, 2010, 13, 403.	1.9	1
348	Evaluation of Psychosocial Impact and Quality of Life in BRCA Mutation Family. Journal of Genetic Medicine, 2010, 7, 67-77.	0.2	3
349	Multiplex genotyping of 1107 SNPs from 232 candidate genes identified an association between IL1A polymorphism and breast cancer risk. Oncology Reports, 2010, 23, 763-9.	2.6	17
350	Factors Affecting the Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy in Patients with T1 and T2 Tumors. Journal of Breast Cancer, 2009, 12, 324.	1.9	5
351	Fibrin Glue Reduces the Duration of Lymphatic Drainage after Lumpectomy and Level II or III Axillary Lymph Node Dissection for Breast Cancer: A Prospective Randomized Trial. Journal of Korean Medical Science, 2009, 24, 92.	2.5	29
352	The Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Report. Journal of Breast Cancer, 2009, 12, 92.	1.9	17
353	Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1357-1364.	2.5	56
354	Preoperative Sonographic Classification of Axillary Lymph Nodes in Patients With Breast Cancer: Node-to-Node Correlation With Surgical Histology and Sentinel Node Biopsy Results. American Journal of Roentgenology, 2009, 193, 1731-1737.	2.2	115
355	Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Annals of Oncology, 2009, 20, 636-641.	1.2	51
356	Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. Carcinogenesis, 2009, 30, 1528-1531.	2.8	57
357	Serum High-Density Lipoprotein Cholesterol and Breast Cancer Risk by Menopausal Status, Body Mass Index, and Hormonal Receptor in Korea. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 508-515.	2.5	62
358	Underweight and Breast Cancer Recurrence and Death: A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology, 2009, 27, 5899-5905.	1.6	91
359	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2009, 116, 153-160.	2.5	41
360	Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population. Familial Cancer, 2009, 8, 505-508.	1.9	20

#	Article	IF	CITATIONS
361	Results of breastâ€conserving therapy for multifocal or multicentric breast cancers. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 200-205.	1.1	1
362	Comprehensive mutational analysis of <i>BRCA1/BRCA2</i> for Korean breast cancer patients: evidence of a founder mutation. Clinical Genetics, 2009, 76, 152-160.	2.0	32
363	Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 1112-1121.	1.5	76
364	The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. American Journal of Surgery, 2009, 197, 266-269.	1.8	56
365	Abstract C26: Nuclear factor I/B regulates cell proliferation of ER negative breast cancer. , 2009, , .		Ο
366	CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk. Breast Cancer Research and Treatment, 2008, 110, 387-393.	2.5	15
367	Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Research and Treatment, 2008, 112, 189-195.	2.5	71
368	Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. Journal of Surgical Oncology, 2008, 98, 15-20.	1.7	48
369	Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. International Journal of Cancer, 2008, 123, 1807-1815.	5.1	41
370	DNA copy number alterations and expression of relevant genes in tripleâ€negative breast cancer. Genes Chromosomes and Cancer, 2008, 47, 490-499.	2.8	91
371	What Is the Best?. Annals of Surgical Oncology, 2008, 15, 3317-3317.	1.5	2
372	A Scoring System to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients with Metastatic Sentinel Lymph Nodes: A Comparison with Other Scoring Systems. Annals of Surgical Oncology, 2008, 15, 2278-2286.	1.5	42
373	ESR1 gene amplification in breast cancer: a common phenomenon?. Nature Genetics, 2008, 40, 807-808.	21.4	53
374	CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer, 2008, 8, 118.	2.6	13
375	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer, 2008, 8, 307.	2.6	108
376	Fatigue and Depression in Disease-Free Breast Cancer Survivors: Prevalence, Correlates, and Association with Quality of Life. Journal of Pain and Symptom Management, 2008, 35, 644-655.	1.2	212
377	<i>CAMK1D</i> amplification implicated in epithelial–mesenchymal transition in basalâ€ŀike breast cancer. Molecular Oncology, 2008, 2, 327-339.	4.6	55
378	Ongoing debates in the assessment of the HER2 status in breast cancer: A comparative analysis by immunohistochemistry and FISH using original FDA and ASCO/CAP guidelines. Basic and Applied Pathology, 2008, 1, 182-188.	0.2	1

#	Article	IF	CITATIONS
379	Berberine Diminishes the Side Population and ABCG2 Transporter Expression in MCF-7 Breast Cancer Cells. Planta Medica, 2008, 74, 1693-1700.	1.3	43
380	Berberine Inhibits Growth of the Breast Cancer Cell Lines MCF-7 and MDA-MB-231. Planta Medica, 2008, 74, 39-42.	1.3	50
381	The Axillary Arch of Langer (Axillopectoral Muscle): A Case Report. Journal of Breast Cancer, 2008, 11, 106.	1.9	1
382	Results of Breast Conserving Surgery and Subsequent Postoperative Radiotherapy for Cases of Breast Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 142.	0.1	2
383	Poor Outcome of Hormone Receptor–Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea—A Report From the Korean Breast Cancer Society. Journal of Clinical Oncology, 2007, 25, 2360-2368.	1.6	217
384	BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Letters, 2007, 245, 90-95.	7.2	52
385	Isolation of CD24high and CD24low/â^' cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Letters, 2007, 258, 98-108.	7.2	33
386	Toremifene as an Adjuvant Hormone Therapy for Estrogen Receptor Positive early Breast Cancer: Therapeutic Efficacy and Effect on Endometrium. Journal of Breast Cancer, 2007, 10, 258.	1.9	3
387	Downregulation of the RUNX3 Gene by Promoter Hypermethylation and Hemizygous Deletion in Breast Cancer. Journal of Korean Medical Science, 2007, 22, S24.	2.5	26
388	Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. Journal of Cellular Biochemistry, 2007, 101, 1038-1045.	2.6	44
389	Concurrent versus Sequential Administration of CMF Chemotherapy and Radiotherapy After Breast Conserving Surgery in Early Breast Cancer: A Retrospective Comparative Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, S222.	0.8	0
390	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer, 2007, 7, 203.	2.6	126
391	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer, 2007, 7, 63.	2.6	63
392	Discovery and validation of breast cancer subtypes. BMC Genomics, 2007, 8, 101.	2.8	2
393	Endoscopic Thyroidectomy Using a New Bilateral Axilloâ€Breast Approach. World Journal of Surgery, 2007, 31, 601-606.	1.6	335
394	Endoscopic Thyroidectomy for Thyroid Malignancies: Comparison with Conventional Open Thyroidectomy. World Journal of Surgery, 2007, 31, 2302-2306.	1.6	190
395	Factors affecting health-related quality of life in women with recurrent breast cancer in Korea. Quality of Life Research, 2007, 16, 559-569.	3.1	16
396	Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. Breast Cancer Research and Treatment, 2007, 106, 433-438.	2.5	29

#	Article	IF	CITATIONS
397	Alteration of Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Breast Cancer after Neoadjuvant Chemotherapy. Journal of Breast Cancer, 2007, 10, 206.	1.9	5
398	The Clinical and Histopathological Characteristics of Male Breast Cancer Patients. Journal of Breast Cancer, 2007, 10, 211.	1.9	6
399	The Policy Proposal for Effective Prevention and Management of Breast Cancer. Journal of Breast Cancer, 2006, 9, 270.	1.9	5
400	Genetic Polymorphisms of eNOS, Hormone Receptor Status, and Survival of Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 213-218.	2.5	37
401	Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer, 2006, 6, 92.	2.6	63
402	Discovery and validation of breast cancer subtypes. BMC Genomics, 2006, 7, 231.	2.8	102
403	Postoperative Survival and Prognostic Factors in Breast Cancer : a Single Center Analysis of 4,063 Cases. Journal of Breast Cancer, 2006, 9, 55.	1.9	3
404	A case of Breast Gigantism in a Patient with Wilson's Disease treated by Penicillamine. Journal of Breast Cancer, 2006, 9, 69.	1.9	2
405	Usefulness of Ki-67 as a prognostic Factor in Lymph Node-Negative Breast Cancer. Journal of Breast Cancer, 2006, 9, 41.	1.9	2
406	Preoperative Evaluation of Lymph Node Metastasis with Using Ultrasonography for Examining the Axilla in Early Stage Breast Cancer. Journal of Breast Cancer, 2006, 9, 115.	1.9	2
407	A streamlined platform for high-content functional proteomics of primary human specimens. Nature Methods, 2005, 2, 691-697.	19.0	225
408	Pix-a enhances the activity of phospholipase C?1 by binding SH3 domain in breast cancer. Journal of Cellular Biochemistry, 2005, 94, 1010-1016.	2.6	9
409	The clinical use of staging bone scan in patients with breast carcinoma. Cancer, 2005, 104, 499-503.	4.1	22
410	Genetic Polymorphisms of Ataxia Telangiectasia Mutated and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 821-825.	2.5	48
411	Genetic Polymorphisms of SULT1A1 and SULT1E1 and the Risk and Survival of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1090-1095.	2.5	52
412	A Haplotype Analysis of HER-2 Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea. Clinical Cancer Research, 2005, 11, 4775-4778.	7.0	44
413	The Clinicopathologic Characteristics of 38 Metaplastic Carcinomas of the Breast. Journal of Breast Cancer, 2005, 8, 59.	1.9	8
414	Ultrasound Assessment of Invasive Breast Cancer: Correlation with Histologic Grade. Journal of the Korean Radiological Society, 2005, 52, 279.	0.0	0

#	Article	IF	CITATIONS
415	The Relationship between Abnormal Screening Bone Scintigraphy and Bone Metastasis in Breast Cancer Patients. Journal of Breast Cancer, 2005, 8, 56.	1.9	0
416	Associations between Breast Cancer Susceptibility Gene Polymorphisms and Clinicopathological Features. Clinical Cancer Research, 2004, 10, 124-130.	7.0	47
417	Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Experimental and Molecular Medicine, 2004, 36, 116-121.	7.7	64
418	Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer, 2004, 4, 82.	2.6	197
419	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. Cancer, 2004, 101, 2516-2522.	4.1	14
420	Determining the Main Risk Factors and High-risk Groups of Breast Cancer Using a Predictive Model for Breast Cancer Risk Assessment in South Korea. Cancer Nursing, 2004, 27, 400???406.	1.5	31
421	Analysis of Hypoparathyroidism after Thyroid Surgery. The Korean Journal of Endocrine Surgery, 2004, 4, 36.	0.1	0
422	Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells. Anticancer Research, 2004, 24, 3961-4.	1.1	25
423	hOGG1 Ser 326 Cys Polymorphism and Breast Cancer Risk among Asian Women. Breast Cancer Research and Treatment, 2003, 79, 59-62.	2.5	49
424	Phospholipase C-protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis. Journal of Cellular Biochemistry, 2003, 89, 520-528.	2.6	15
425	Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. Pharmacogenetics and Genomics, 2003, 13, 67-72.	5.7	64
426	Protective Role of Prx(Peroxiredoxin) I and II against H2O2-Induced Apoptosis of MCF7 Cell Lines. Journal of Korean Breast Cancer Society, 2003, 6, 68.	0.1	0
427	Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its association with breast cancer risk. Anticancer Research, 2003, 23, 4703-7.	1.1	6
428	Gene Expression Profiles of Primary Breast Cancer Tissue Using cDNA Microarray. Journal of Korean Breast Cancer Society, 2002, 5, 284.	0.1	2
429	The Usefulness of Ultrasound Surveillance for Axillary Recurrence in Women With Personal History of Breast Cancer. Journal of Breast Cancer, 0, 24, .	1.9	0
430	Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing. Journal of Breast Cancer, 0, 25, .	1.9	1